COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis (GPP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03619902
Recruitment Status : Recruiting
First Posted : August 8, 2018
Last Update Posted : July 2, 2019
Information provided by (Responsible Party):
AnaptysBio, Inc.

Brief Summary:
A study investigating the efficacy and safety, and pharmacokinetic (PK) profile of ANB019 in subjects with generalized pustular psoriasis

Condition or disease Intervention/treatment Phase
Generalized Pustular Psoriasis Drug: ANB019 Phase 2

Detailed Description:
This is a Phase II single arm multiple dose study to assess the efficacy and safety, and PK of ANB019 in subjects with Generalized Pustular Psoriasis

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Arm Multiple Dose Study to Assess the Efficacy and Safety of ANB019 in Subjects With Generalized Pustular Psoriasis
Actual Study Start Date : March 4, 2019
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : December 2019

Arm Intervention/treatment
Experimental: ANB019 Biological/Vaccine
ANB019 subcutaneous (SC) injection every 4 weeks
Drug: ANB019
Humanized Monoclonal Antibody

Primary Outcome Measures :
  1. Proportion of subjects achieving clinical response on the Clinical Global Impression (CGI) scale [ Time Frame: Baseline to Week 16 ]
    CGI scale is used to assess the clinical response to treatment. CGI has five categories: very much improved, much improved, minimally improved, no change, and worsened. Clinically meaningful response is defined as "very much improved', "much improved", minimally improved" on CGI severity index scale.

  2. Incidence of Adverse Events (AEs) [ Time Frame: Baseline to Week 24 ]
    Treatment emergent AEs are defined as a new event that occurs during or after first dose of study treatment, including any clinical significant laboratory values and vital signs.

Secondary Outcome Measures :
  1. Change from baseline in total and individual components of modified Japanese Dermatology Association Severity Index (mJDA) for GPP. [ Time Frame: Baseline to Week 16 ]
    The modified JDA severity index has seven components: erythema, erythema with pustules and edema, fever and WBCs, CRP, and serum albumin. Skin lesions each score 0-3, each parameter (fever, WBCs, CRP, albumin) score 0-2, and the total mJDA severity score ranges 0-17.

  2. Change from baseline in Dermatology Life Quality instruments (DLQI) [ Time Frame: Baseline to Week 16 ]
    The DLQI is a 10-item questionnaire to assess limitations related to the impact of skin disease. The aim is to measure how much the skin condition has affected the subjects life including daily activities, work/school, personal relationships and treatment. The total score has a possible range of 0 to 30, with higher score corresponding to the worst quality of life.

  3. Determination pharmacokinentics (PK) of ANB019 in patients with Generalized Pustular Psoriasis (GPP) [ Time Frame: Baseline to Week 24 ]
    Serum concentration will be measured following ANB019 administration

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of active GPP
  • Total JDA score of at least 6 and erythema with pustules accounting for at least 10% or a moderate severity score on GPPPGA
  • Must be candidates for systemic therapy or phototherapy

Exclusion Criteria:

  • Erythrodermic, guttate psoriasis, drug induced GPP
  • Any other ongoing inflammatory disease that interfere with the Investigator's ability to evaluate the subject's response to therapy
  • History of recurrent or chronic infection
  • ongoing use of psoriasis prohibited medication

Other protocol-defined inclusion/exclusion criteria may apply

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03619902

Layout table for location contacts
Contact: AnaptysBio, Inc 858-362-6295

Layout table for location information
United States, California
Encino Research Group Recruiting
Encino, California, United States, 91436
United States, Indiana
DFCRG Recruiting
Indianapolis, Indiana, United States, 46250
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
United States, Rhode Island
Clinical Partners, LLC Recruiting
Johnston, Rhode Island, United States, 02919
United Kingdom
St Thomas' Hospital Recruiting
London, United Kingdom
Newcastle University Recruiting
Newcastle Upon Tyne, United Kingdom
Salford Royal Recruiting
Salford, United Kingdom
Sponsors and Collaborators
AnaptysBio, Inc.
Layout table for investigator information
Study Director: Irina Khanskaya, MD AnaptysBio, Inc.
Additional Information:
Layout table for additonal information
Responsible Party: AnaptysBio, Inc. Identifier: NCT03619902    
Other Study ID Numbers: ANB019-002
First Posted: August 8, 2018    Key Record Dates
Last Update Posted: July 2, 2019
Last Verified: July 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by AnaptysBio, Inc.:
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases